Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • New toxic drug...

New toxic drug impurities detected in some heart pills in US: Bloomberg

Ruchika SharmaWritten by Ruchika Sharma Published On 2021-10-15T09:15:42+05:30  |  Updated On 13 Oct 2023 3:50 PM IST
New toxic drug impurities detected in some heart pills in US: Bloomberg
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: Over the past three years, millions of blood pressure pills that contain a probable carcinogen have been recalled around the world. As pharmaceutical companies have worked on finding a fix, they've discovered an entirely new problem: Another potentially dangerous chemical is showing up in the same drugs.

The new chemicals are called azido impurities and regulatory authorities say they're mutagenic, meaning they can change someone's DNA and potentially increase cancer risk.
The impurities were found in blood pressure drugs which have been recalled in Canada as well as Europe earlier this year. U.S. officials helped lead the way in the 2018 recalls of the same type of drugs tainted with the probable carcinogen N-Nitrosodimethylamine, or NDMA, though they have yet to pull any for containing the azido impurities.
Meanwhile, a U.S. Food and Drug Administration inspector has found at least one large manufacturer in India, Hetero Labs Ltd., has a flawed process for controlling the impurities, according to documents reviewed by Bloomberg. Hetero also hasn't adequately ensured a residue of impurities aren't building up on production equipment, which can cross-contaminate subsequent batches, according to the documents.
The FDA inspector visited Hetero Labs Ltd.'s production plant in the Sangareddy district in south central India over 10 days in August. The plant makes the active ingredient for the blood pressure drug called valsartan, which it sells to other pharmaceutical companies to make a finished pill. Valsartan production can form azido impurities. The company did not respond to requests for comment.
Drug regulator Health Canada announced recalls of
valsartan
, a type of drug called an angiotensin II receptor blocker or ARB, in May for elevated levels of azido impurities. Over the next few months, other drugs in the same class, losartan and irbesartan, were recalled for the same impurities. Companies implicated include Sanofi, Novartis AG's generic-drug unit Sandoz and generic-drug giant Teva Pharmaceutical Industries Ltd.
Teva also recalled ARBs in the U.K. in June followed by Sanofi in August, according to the country's Medicines and Healthcare products Regulatory Agency. The MHRA is aware of three potential azido impurities in heart drugs, according to emailed answers to a list of questions from Bloomberg. Other European countries have also recalled ARBs containing azido impurities, including France, Switzerland and Ireland.
Sanofi recalled certain drugs containing irbesartan in Canada in June for elevated levels of azido impurities and sold some of those same drugs in the U.S., a spokesperson said in an email response to Bloomberg. The drugmaker informed the U.S. FDA and didn't receive any further feedback, the spokesperson said.
Sanofi is close to completing testing of all batches of irbesartan-containing medicine produced between 2018 and 2020. Most have not contained levels of azido impurities above the threshold considered acceptable. The company plans to collaborate with health authorities in mid-October to propose recalls of any non-conforming batches, the spokesperson said. The impurities are a by-product of a previous manufacturing process and Sanofi's irbesartan tested since January has not contained unacceptable levels of azido impurities, according to the spokesperson.
Sandoz originally recalled 40 batches of ARBs in Canada in May and has since recalled 49 batches of certain losartan pills there. The active ingredient for the drugs was made by another company, according to an emailed statement from a spokesperson for parent company Novartis, though the company wasn't named.
Sanofi and Sandoz both were involved in another major recall in 2019 related to NDMA-tainted drugs that led the heartburn medication Zantac and its generics to be pulled from the market. The independent testing lab Valisure, based in New Haven, Connecticut, first discovered NDMA in the medication and flagged regulators. The active ingredient in Zantac, ranitidine, was found to form NDMA over time or when stored at high temperatures.
Zantac wasn't the last recall related to NDMA or chemicals like it, which fall under a class called nitrosamines. Last year, the widely used diabetes drug metformin was recalled for NDMA contamination and Pfizer Inc. recalled all lots of its smoking cessation pill Chantix last month after it was found to contain a nitrosamine.
In 2018, Hetero supplied the active ingredient to some of the companies that had to pull their drugs because they contained NDMA and other similar chemicals. While the recalls started that same year, regulators and industry continued to find additional contamination from chemicals similar to NDMA in the blood pressure pills valsartan, losartan and irbesartan, resulting in recalls that stretched out over almost two years as tainted drugs were identified. The NDMA was likely formed as a part of the manufacturing process for the active ingredients, though drugmakers and regulators didn't catch the problem for many years.
The FDA declined to address whether it has found drugs that contain azido impurities or if it anticipates any recalls in the U.S.
"We have been closely evaluating this type of impurity, working with manufacturers and foreign authorities, and will continue to investigate and monitor the marketplace and manufacturing efforts to help ensure the availability of safe, quality products for U.S. consumers," Jeremy Kahn, a spokesman said in an email.
Hetero's production plant in the Sangareddy district is one of the company's 10 facilities in India registered with the FDA to help make drugs sold to the United States. It was last inspected in 2018 and received the agency's worst classification, which means it's likely the company would have a hard time getting FDA approval to make any new drugs there until it clears up its issues. But the agency typically allows companies with long lists of violations stemming from inspections to continue to make drugs they're already allowed to produce at substandard plants while they work on fixing their problems.
The documents also point out a material used early in the drug-making process plays a role in creating azido impurities. While Hetero's production guidelines call for keeping that material to a certain level to avoid forming unacceptable impurity levels, the company's study used to determine that safe level is faulty, according to the FDA documents.
The FDA, spokesman Kahn said, cannot comment on whether it would take any action against Hetero.
Read also: Single shot Sputnik Light shows 70 percent efficacy against Covid Delta variant: RDIF




carcinogenblood pressureazido impuritiescancerhetero labsvalsartanlosartanirbesartansanofinovartissandozteva pharmazantacranitidinechantixpfizer
Source : Bloomberg
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok